Press release
Eosinophilic Esophagitis Clinical Trials 2024: FDA Approvals, Medication, Therapies, Treatment Market, MOA, ROA and Companies by DelveInsight
Eosinophilic Esophagitis Clinical Trials
Key Takeaways from the Eosinophilic Esophagitis Pipeline Report
• DelveInsight's Eosinophilic Esophagitis pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Eosinophilic Esophagitis treatment.
• The leading companies working in the Eosinophilic Esophagitis Market include AstraZeneca, Bristol Myers Squibb, Ellodi Pharmaceuticals, Allakos, EsoCap AG, Arena Pharmaceuticals, GlaxoSmithKline, Landos Biopharma, Calypso Biotech, Takeda, Dr Falk Pharma, DBV Technologies, Revolo Biotherapeutics, EsoCap, Aqilion, Serpin Pharma, and others.
• Promising Eosinophilic Esophagitis Pipeline Therapies in the various stages of development include Tezepelumab, Etrasimod, Reslizumab, Dupilumab, ESO-101, NDX-3315, and others.
• April 2024:- AstraZeneca- A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients With Eosinophilic Esophagitis (CROSSING). The study consists of a screening period of 2 to 8 weeks and a 52-week randomized double-blind placebo-controlled treatment period. After completion of the treatment period, participants will be eligible to participate in an optional active treatment extension period (lasting for 24 weeks), followed by a 12-week off-treatment safety follow-up period. Participants who will not participate in the extension period will participate in a 12-week off-treatment safety follow-up period following completion of the 52-week treatment period.
• April 2024:- Ellodi Pharmaceuticals, LP- Fluticasone Propionate Oral Disintegrating Tablet Formulation in Eosinophilic Esophagitis: A Randomized, Double-blind, Placebo-Controlled 24-Week Induction Study of APT-1011, Followed by a Single-arm Open-label Extension, in Adult Subjects With Eosinophilic Esophagitis.
Request a sample and discover the recent advances in Eosinophilic Esophagitis Treatment Drugs @ Eosinophilic Esophagitis Pipeline Report- https://www.delveinsight.com/report-store/eosinophilic-esophagitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
In the Eosinophilic Esophagitis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details. Eosinophilic
Eosinophilic Esophagitis Overview
Eosinophilic Esophagitis (EoE) is a chronic, immune-mediated inflammatory disease of the esophagus characterized by the presence of a high number of eosinophils (a type of white blood cell) in the esophageal lining. It primarily results from a hypersensitive immune response to specific foods or environmental allergens. EoE is increasingly recognized as a significant cause of swallowing difficulties and food impaction in both adults and children.
Symptoms vary with age. Children may experience feeding difficulties, abdominal pain, or failure to thrive, while adults often present with dysphagia (difficulty swallowing), chest pain, or food getting stuck in the esophagus. Left untreated, EoE can lead to esophageal narrowing, strictures, and fibrosis.
Diagnosis involves endoscopy with esophageal biopsies to identify eosinophilic infiltration. Management strategies include dietary interventions (elimination diets), pharmacological treatments (topical corticosteroids, proton pump inhibitors), and dilation procedures for severe strictures. Emerging therapies, such as biologics targeting specific immune pathways, offer promise for more targeted treatment.
EoE prevalence is rising globally, likely due to increased awareness and changing environmental factors. While not life-threatening, EoE significantly impacts quality of life, emphasizing the need for early diagnosis and multidisciplinary care involving allergists, gastroenterologists, and dietitians.
Find out more about Eosinophilic Esophagitis Therapeutics Assessment @ Eosinophilic Esophagitis Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Eosinophilic Esophagitis Emerging Drugs Profile
• APT-1011: Ellodi Pharmaceuticals.
DelveInsight's Eosinophilic Esophagitis Pipeline Report covers around 20+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Eosinophilic Esophagitis Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intravenous
Eosinophilic Esophagitis Pipeline Products have been categorized under various Molecule types such as
• Peptide
• Protein
• Propylene glycols
• Cell Therapy
Eosinophilic Esophagitis Pipeline Therapeutics Assessment
There are approx. 18+ key companies which are developing the Eosinophilic Esophagitis therapies. The Eosinophilic Esophagitis companies which have their Eosinophilic Esophagitis drug candidates in the most advanced stage, i.e. Phase III include, Ellodi Pharmaceuticals.
Learn more about the emerging Eosinophilic Esophagitis Pipeline Therapies @ Eosinophilic Esophagitis Clinical Trials Assessment- https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Eosinophilic Esophagitis Pipeline Report
• Coverage- Global
• Eosinophilic Esophagitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Eosinophilic Esophagitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Eosinophilic Esophagitis Companies- AstraZeneca, Bristol Myers Squibb, Ellodi Pharmaceuticals, Allakos, EsoCap AG, Arena Pharmaceuticals, GlaxoSmithKline, Landos Biopharma, Calypso Biotech, Takeda, Dr Falk Pharma, DBV Technologies, Revolo Biotherapeutics, EsoCap, Aqilion, Serpin Pharma, and others.
• Eosinophilic Esophagitis Pipeline Therapies- Tezepelumab, Etrasimod, Reslizumab, Dupilumab, ESO-101, NDX-3315, and others.
Dive deep into rich insights for new drugs for Eosinophilic Esophagitis Treatment, Visit @ Eosinophilic Esophagitis Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Content
1. Introduction
2. Executive Summary
3. Eosinophilic Esophagitis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Eosinophilic Esophagitis - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Benralizumab: AstraZeneca
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. IRL201104: Revolo Biotherapeutics
12. Drug profiles in the detailed report…..
13. Mid Stage Products (Phase II)
14. Mometasone: EsoCap
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. AQ280: Aqilion
18. Drug profiles in the detailed report…..
19. Preclinical and Discovery Stage Products
20. SP 16: Serpin Pharma
21. Drug profiles in the detailed report…..
22. Inactive Products
23. Eosinophilic Esophagitis Key Companies
24. Eosinophilic Esophagitis Key Products
25. Eosinophilic Esophagitis- Unmet Needs
26. Eosinophilic Esophagitis- Market Drivers and Barriers
27. Eosinophilic Esophagitis- Future Perspectives and Conclusion
28. Eosinophilic Esophagitis Analyst Views
29. Eosinophilic Esophagitis Key Companies
30. Appendix
For further information on the Eosinophilic Esophagitis Pipeline therapeutics, reach out to Eosinophilic Esophagitis Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Trending Report:
• Acute Heart Failure Market: https://www.delveinsight.com/report-store/acute-heart-failure-ahf-market
• Acute On Chronic Liver Failure Aclf Market: https://www.delveinsight.com/report-store/acute-on-chronic-liver-failure-aclf-market
• Acute Respiratory Distress Syndrome Market: https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-ards-market
• Adult Myopia Market: https://www.delveinsight.com/infographics/adult-myopia-market
• Advanced Cancer Pain Management Market: https://www.delveinsight.com/report-store/advanced-cancer-pain-management-market
• Anorectal Malformation Market: https://www.delveinsight.com/report-store/anorectal-malformation-market
• Arthralgia Market: https://www.delveinsight.com/report-store/arthralgia-market
• Becker Muscular Dystrophy Market: https://www.delveinsight.com/report-store/becker-muscular-dystrophy-market
• Bipolar Depression Market: https://www.delveinsight.com/report-store/bipolar-disorder-manic-depression-market
• Charcot Marie Tooth Disease Market: https://www.delveinsight.com/report-store/charcot-marie-tooth-disease-market
• Checkpoint Inhibitor Refractory Cancer Market: https://www.delveinsight.com/report-store/checkpoint-inhibitor-refractory-cancer-market
• Chronic Pulmonary Infection Market: https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market
• Clbp Market: https://www.delveinsight.com/report-store/chronic-lower-back-pain-clbp-market
• Condyloma Market: https://www.delveinsight.com/report-store/genital-warts-condyloma-acuminatum-market
• Ctcl Market: https://www.delveinsight.com/report-store/cutaneous-t-cell-lymphoma-ctcl-market
• Cutaneous Lupus Market: https://www.delveinsight.com/report-store/cutaneous-lupus-erythematosus-market
• Cystinosis Market: https://www.delveinsight.com/report-store/cystinosis-market
• Cystinuria Market: https://www.delveinsight.com/report-store/cystinuria-market-insights
• Diffuse Intrinsic Pontine Glioma Dipg Market: https://www.delveinsight.com/report-store/diffuse-intrinsic-pontine-glioma-dipg-market
• Diffuse Large B-cell Lymphoma Market: https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-market
• Digestive System Fistula Market: https://www.delveinsight.com/report-store/digestive-system-fistula-market
• Diverticulitis Market: https://www.delveinsight.com/report-store/diverticulitis-market
• Dlbcl Market: https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-market
• Eosinophilic Gastroenteritis Market: https://www.delveinsight.com/report-store/eosinophilic-gastroenteritis-ege-market
• Epilepsy Market: https://www.delveinsight.com/report-store/epilepsy-market
• Erectile Dysfunction Devices Market: https://www.delveinsight.com/report-store/erectile-dysfunction-devices-market
• Erythema Market: https://www.delveinsight.com/report-store/erythema-market
• Erythromelalgia Market: https://www.delveinsight.com/report-store/erythromelalgia-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/rare-diseases
Case study: https://www.delveinsight.com/case-study/breast-cancer-market-dynamics-dashboard
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Eosinophilic Esophagitis Clinical Trials 2024: FDA Approvals, Medication, Therapies, Treatment Market, MOA, ROA and Companies by DelveInsight here
News-ID: 3748732 • Views: …
More Releases from DelveInsight Business Research
Geographic Atrophy Clinical Trial Analysis: 25+ Drugs, 23+ Companies Redefining …
DelveInsight's newly released report, "Geographic Atrophy Pipeline Insight" offers a comprehensive analysis of the evolving Geographic Atrophy (GA) therapeutic landscape, covering 23+ biopharmaceutical companies and 25 investigational drug candidates. The report features in-depth profiles of both clinical- and preclinical-stage assets, along with a detailed therapeutic assessment categorized by product type, development phase, route of administration, and molecular class. It also provides visibility into inactive and discontinued pipeline programs within the…
Interstitial Lung Disease Clinical Trial Analysis: 120+ Drugs and 120+ Companies …
DelveInsight, a prominent market intelligence and consulting organization in the life sciences domain, has announced the launch of its newest report titled "Interstitial Lung Disease Pipeline Insight, 2025." The publication delivers a comprehensive analysis of the fast-advancing therapeutic environment for Interstitial Lung Disease (ILD). With over 120 biopharmaceutical companies actively developing 120+ pipeline assets, the ILD pipeline is witnessing remarkable growth fueled by strong scientific innovation, clinical progress, and regulatory…
Global Vein Illumination Devices Market Forecast to Reach USD 152.83 Million by …
DelveInsight's latest publication, "Vein Illumination Devices Market Insights, Competitive Landscape and Market Forecast-2032," offers a comprehensive analysis of existing and future market dynamics. The report examines evolving trends, technological advancements, key market challenges, growth catalysts, and limiting factors, while also showcasing upcoming product launches and profiling the major players influencing the vein illumination devices industry.
Based on DelveInsight's most recent evaluation, the global vein illumination devices market is anticipated to experience…
Liver Cancer Clinical Trial Analysis: 75+ Drugs, 70+ Companies Redefining the Fu …
DelveInsight's "Liver Cancer Pipeline Insights 2025" delivers an in-depth overview of the liver cancer pipeline ecosystem, profiling more than 70 companies and 75+ therapeutic candidates under development. The report thoroughly examines liver cancer drug profiles across both clinical and preclinical stages. It also evaluates the therapeutic landscape by product category, development phase, route of administration, and molecular class, while additionally identifying inactive and discontinued assets within the pipeline.
Stay informed with…
More Releases for Eosinophilic
Eosinophilic Esophagitis Market to Surge to USD 4.1 Billion by 2034
Eosinophilic Esophagitis (EoE) is a chronic, immune-mediated inflammatory condition of the esophagus, characterized by eosinophil infiltration, difficulty swallowing, food impaction, and chest pain. Once considered rare, EoE has now emerged as one of the most common causes of dysphagia in children and adults, particularly in developed nations. Strong associations with allergic conditions such as asthma, eczema, and food allergies underscore its complex immunological nature.
Download Full PDF Sample Copy of Market…
Eosinophilic Asthma Treatment Market Outlook and Future Projections for 2030
The eosinophilic asthma treatment market represents a dynamic and continually evolving landscape, shaped by changing consumer demands and technological advancements. In this comprehensive report, we provide an in-depth exploration of the market, designed for a wide range of stakeholders including manufacturers, suppliers, distributors, and investors. Our goal is to equip industry participants with essential insights that enable informed decision-making in an ever-changing market environment. This analysis not only examines the…
Severe Eosinophilic Asthma Treatment Market Outlook and Future Projections for 2 …
The severe eosinophilic asthma treatment market represents a dynamic and continually evolving landscape, shaped by changing consumer demands and technological advancements. In this comprehensive report, we provide an in-depth exploration of the market, designed for a wide range of stakeholders including manufacturers, suppliers, distributors, and investors. Our goal is to equip industry participants with essential insights that enable informed decision-making in an ever-changing market environment. This analysis not only examines…
Eosinophilic Esophagitis Pipeline, Clinical Trials Assessment, Emerging Therapie …
DelveInsight's, "Eosinophilic Esophagitis Pipeline Insight" report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Eosinophilic Esophagitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Eosinophilic Esophagitis research. Learn more about…
Severe Eosinophilic Asthma Treatment Market Outlook and Future Projections for 2 …
The severe eosinophilic asthma treatment market represents a dynamic and continually evolving landscape, shaped by changing consumer demands and technological advancements. In this comprehensive report, we provide an in-depth exploration of the market, designed for a wide range of stakeholders including manufacturers, suppliers, distributors, and investors. Our goal is to equip industry participants with essential insights that enable informed decision-making in an ever-changing market environment. This analysis not only examines…
Eosinophilic Granulomatosis Treatment Market Size and Overview Upto 2028|
The report comes out as an intelligent and thorough assessment tool as well as a great resource that will help you to secure a position of strength in the global Eosinophilic Granulomatosis Treatment market. It includes Porter's Five Forces and PESTLE analysis to equip your business with critical information and comparative data about the Global Eosinophilic Granulomatosis Treatment Market. We have provided a deep analysis of the vendor landscape to give…
